Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

公告及新聞稿, 監管通知 | 2016-10-12

Director's Share Dealing

London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (

公告及新聞稿, 監管通知 | 2016-08-09

Director's Share Dealing

London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US

公告及新聞稿, 集團 | 2016-08-02

Change of Non-executive Directors

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

公告及新聞稿, 集團 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-08-01

為加快沃利替尼全球研發項目，和黃醫藥與阿斯利康簽署共同開發補充協議

1 個附件

首個以c-Met 異常乳頭狀腎細胞癌（“PRCC”）為適應症的全球III 期臨床試驗將於近期啟動 2016年8月1日：和黃醫藥和阿斯利康今日宣佈在2011年雙方就沃利替尼達成的合作協議的基礎�

查看公告 (PDF)

公告及新聞稿, 集團 | 2016-07-05

Chi-Med to Announce 2016 Half-Year Financial Results

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

公告及新聞稿, 監管通知 | 2016-06-29

Blocklisting Six Monthly Return

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-06-20

和黃醫藥啟動沃利替尼以EGFR突變非小細胞肺癌為適應症的全球II期臨床試驗

1 個附件

擴展的非小細胞肺癌II期臨床試驗啟動，阿斯利康向和黃醫藥支付1000萬美元里程金此研究的開展是基於沃利替尼早先與Tagrisso 或Iressa 聯合用藥治療c-Met擴增非小細胞肺癌的初始小型I

查看公告 (PDF)

公告及新聞稿, 監管通知 | 2016-06-15

Block Admission

London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U

公告及新聞稿, 監管通知 | 2016-05-31

Total Voting Rights

London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-05-13

和黃醫藥完成呋喹替尼以結直腸癌為適應症的III期臨床試驗的患者入組工作，共招募416名患者

1 個附件

2016年5月13日：和黃醫藥今日宣布呋喹替尼（HMPL-013）以結直腸癌為適應症的III 期臨床試驗“ FRESCO” 順利完成患者入組工作。2012年，中國新發結直腸癌病例約為39萬例，呋喹替尼的這項關�

查看公告 (PDF)

公告及新聞稿, 監管通知 | 2016-04-29

Total Voting Rights

London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary

公告及新聞稿, 監管通知 | 2016-04-27

Results of Annual General Meeting

London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas

公告及新聞稿, 集團 | 2016-04-13

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-04-12

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli

公告及新聞稿, 監管通知 | 2016-03-31

Total Voting Rights

London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary

公告及新聞稿, 監管通知 | 2016-03-29

Director's Shareholding

London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi

公告及新聞稿, 監管通知 | 2016-03-23

Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is

公告及新聞稿, 新聞稿, 集團 | 2016-03-22

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

公告及新聞稿, 監管通知 | 2016-03-21

Director's Shareholding

London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen

公告及新聞稿, 腫瘤學 / 免疫學 | 2016-03-21

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s

公告及新聞稿, 集團 | 2016-03-18

Final Prospectus

公告及新聞稿, 集團 | 2016-03-17

Pricing of U.S. Public Offering of ADSs

公告及新聞稿, 新聞報導, 集團 | 2016-03-17

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app

公告及新聞稿, 集團 | 2016-03-15

2015 Annual Report and Notice of Annual General Meeting

London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The

公告及新聞稿, 集團 | 2016-03-07

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

公告及新聞稿, 集團 | 2016-03-04

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f

公告及新聞稿, 集團 | 2016-03-04

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-03-02

和黃醫藥啟動索凡替尼以甲狀腺癌為適應症的II期臨床研究

1 個附件

2016年3月2日：和黃醫藥今日宣布正式啟動索凡替尼（HMPL-012）以局部晚期或放射性碘難治性轉移分化的甲狀腺癌（DTC）或甲狀腺髓樣癌（MTC）為適應症在中國開展的一項開放式II期臨床研究，

下載新聞稿 (PDF)

公告及新聞稿, 集團 | 2016-03-01

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新聞稿, 集團 | 2016-03-01

Final Results for the year ended 31 December 2015

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

公告及新聞稿, 集團 | 2016-02-11

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

公告及新聞稿, 監管通知 | 2016-01-29

Notice of Announcement of 2015 Final Results

London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016. An analyst presentation will be held at 9:00 am on the

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2016-01-15

和黃醫藥在澳洲啟動HMPL-523以血液腫瘤為適應症的I期臨床試驗

1 個附件

2016 年1 月15 日：和黃醫藥今日宣佈在澳洲啟動HMPL-523 以惡性血液腫瘤為適應症的I 期臨床試驗。HMPL-523 是針對B 細胞受體信號通路中的酪氨酸激酶Syk 的新型高選擇性小分子抑製劑。此�

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2015-12-29

Blocklisting Six Monthly Return

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutc

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-12-18

和黃醫藥啟動索凡替尼以神經內分泌瘤為適應症的III期臨床研究

1 個附件

2015 年12 月18 日：和黃醫藥今日宣布正式啟動索凡替尼（HMPL-012）以非胰腺神經內分泌瘤為適應症的中國III 期臨床研究（SANET-ep）。此次研究的受試者均為非胰腺神經內分泌瘤患者，包括�

下載新聞稿 (PDF)

公告及新聞稿, 其他業務, 新聞稿 | 2015-12-09

US$105 million Shanghai land compensation agreement

Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-12-08

和黃醫藥啟動呋喹替尼以非小細胞肺癌為適應症的III期臨床試驗

1 個附件

2015 年12 月8 日: 和黃醫藥今日宣布呋喹替尼（HMPL-013）以晚期非鱗狀非小細胞肺癌為適應症的中國III 期臨床試驗（FALUCA）正式啟動。呋喹替尼是一種新型高選擇性抑制血管細胞內皮生長�

查看公告 (PDF)

公告及新聞稿, 集團 | 2015-11-13

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

公告及新聞稿, 監管通知 | 2015-11-10

Results of Extraordinary General Meeting

London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were

公告及新聞稿, 監管通知 | 2015-11-09

Director's Share Dealing

London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-11-06

和黃醫藥啟動索凡替尼在美國的臨床試驗

1 個附件

2015年11月6日：和黃醫藥今日宣布啟動索凡替尼（HMPL-012）在美國的I期臨床試驗。該藥的美國新藥臨床研究申請於今年遞交並通過，2015年11月4日首位受試者接受給藥治療。此外，和黃醫藥將�

查看公告 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

公告及新聞稿, 監管通知 | 2015-10-30

Total Voting Rights

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-30

和黃醫藥宣布新型Syk 抑製劑HMPL-523治療免疫疾病的I期臨床試驗取得成功

1 個附件

2015 年10 月30 日: 和黃醫藥（上海）有限公司（簡稱“ 和黃醫藥” ）今日宣布成功完成HMPL ‑ 523 的I 期臨床試驗。HMPL-523 是針對B 細胞受體信號通路中的酪氨酸激酶Syk 的新型高選擇�

查看公告 (PDF)

公告及新聞稿, 腫瘤學 / 免疫學 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

公告及新聞稿, 監管通知 | 2015-10-20

Director's Share Dealing

London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi

公告及新聞稿, 監管通知 | 2015-10-19

Awards under Long Term Incentive Plan

London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP

公告及新聞稿, 新聞稿, 集團 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti

1 2 3 4 5 6 7 8 9

11 12 13 14 15